-
Something wrong with this record ?
Number of RUNX1 mutations, wild-type allele loss and additional mutations impact on prognosis in adult RUNX1-mutated AML
A. Stengel, W. Kern, M. Meggendorfer, N. Nadarajah, K. Perglerovà, T. Haferlach, C. Haferlach,
Language English Country England, Great Britain
Document type Journal Article
NLK
ProQuest Central
from 2000-01-01 to 1 year ago
Open Access Digital Library
from 1997-01-01
Nursing & Allied Health Database (ProQuest)
from 2000-01-01 to 1 year ago
Health & Medicine (ProQuest)
from 2000-01-01 to 1 year ago
Public Health Database (ProQuest)
from 2000-01-01 to 1 year ago
PubMed
28751771
DOI
10.1038/leu.2017.239
Knihovny.cz E-resources
- MeSH
- Leukemia, Myeloid, Acute genetics pathology MeSH
- Alleles MeSH
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Adolescent MeSH
- Young Adult MeSH
- Mutation genetics MeSH
- Prognosis MeSH
- Core Binding Factor Alpha 2 Subunit genetics MeSH
- Repressor Proteins genetics MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Loss of Heterozygosity genetics MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Adolescent MeSH
- Young Adult MeSH
- Male MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
RUNX1-mutated acute myeloid leukemia (AML) show a distinct pattern of genetic abnormalities and an adverse prognosis. We analyzed the impact of multiple RUNX1 mutations and RUNX1 wild-type (WT) loss in 467 AML with RUNX1 mutations (mut): (1) RUNX1 WT loss (n=53), (2) >1 RUNX1mut (n=94) and (3) 1 RUNX1mut (n=323). In 1 RUNX1mut, +8 was most frequent, whereas in WT loss +13 was the most abundant trisomy (+8: 66% vs 31%, P=0.022; +13: 15% vs 62%, P<0.001). Analyses of 28 genes in 163 selected cases revealed SRSF2 (39%), ASXL1 (36%), DNMT3A (19%), IDH2 (17%) and SF3B1 (17%) as most frequently mutated genes. RUNX1 WT loss showed a higher frequency of ASXL1mut compared with the other cases (50% vs 29%, P=0.009). Median overall survival (OS) in the total cohort was 14 months. WT loss (OS: 5 months) and >1 RUNX1mut (14 months) showed an adverse impact on prognosis compared with 1 RUNX1mut (22 months; P=0.002 and 0.048, respectively). Mutations in ASXL1 and ⩾2 additional mutations correlated with shorter OS (10 vs 18 months, P=0.028; 12 vs 20 months, P=0.017). Thus, the number of RUNX1mut, RUNX1 WT loss and the number and type of additional mutations is biologically and clinically relevant.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc19013112
- 003
- CZ-PrNML
- 005
- 20190412121751.0
- 007
- ta
- 008
- 190405s2018 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1038/leu.2017.239 $2 doi
- 035 __
- $a (PubMed)28751771
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Stengel, A $u MLL Munich Leukemia Laboratory, Munich, Germany.
- 245 10
- $a Number of RUNX1 mutations, wild-type allele loss and additional mutations impact on prognosis in adult RUNX1-mutated AML / $c A. Stengel, W. Kern, M. Meggendorfer, N. Nadarajah, K. Perglerovà, T. Haferlach, C. Haferlach,
- 520 9_
- $a RUNX1-mutated acute myeloid leukemia (AML) show a distinct pattern of genetic abnormalities and an adverse prognosis. We analyzed the impact of multiple RUNX1 mutations and RUNX1 wild-type (WT) loss in 467 AML with RUNX1 mutations (mut): (1) RUNX1 WT loss (n=53), (2) >1 RUNX1mut (n=94) and (3) 1 RUNX1mut (n=323). In 1 RUNX1mut, +8 was most frequent, whereas in WT loss +13 was the most abundant trisomy (+8: 66% vs 31%, P=0.022; +13: 15% vs 62%, P<0.001). Analyses of 28 genes in 163 selected cases revealed SRSF2 (39%), ASXL1 (36%), DNMT3A (19%), IDH2 (17%) and SF3B1 (17%) as most frequently mutated genes. RUNX1 WT loss showed a higher frequency of ASXL1mut compared with the other cases (50% vs 29%, P=0.009). Median overall survival (OS) in the total cohort was 14 months. WT loss (OS: 5 months) and >1 RUNX1mut (14 months) showed an adverse impact on prognosis compared with 1 RUNX1mut (22 months; P=0.002 and 0.048, respectively). Mutations in ASXL1 and ⩾2 additional mutations correlated with shorter OS (10 vs 18 months, P=0.028; 12 vs 20 months, P=0.017). Thus, the number of RUNX1mut, RUNX1 WT loss and the number and type of additional mutations is biologically and clinically relevant.
- 650 _2
- $a mladiství $7 D000293
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a senioři nad 80 let $7 D000369
- 650 _2
- $a alely $7 D000483
- 650 _2
- $a protein PEBP2A2 $x genetika $7 D050676
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a akutní myeloidní leukemie $x genetika $x patologie $7 D015470
- 650 _2
- $a ztráta heterozygozity $x genetika $7 D019656
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a mutace $x genetika $7 D009154
- 650 _2
- $a prognóza $7 D011379
- 650 _2
- $a represorové proteiny $x genetika $7 D012097
- 650 _2
- $a mladý dospělý $7 D055815
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Kern, W $u MLL Munich Leukemia Laboratory, Munich, Germany.
- 700 1_
- $a Meggendorfer, M $u MLL Munich Leukemia Laboratory, Munich, Germany.
- 700 1_
- $a Nadarajah, N $u MLL Munich Leukemia Laboratory, Munich, Germany.
- 700 1_
- $a Perglerovà, K $u MLL2, Praha, Czech Republic.
- 700 1_
- $a Haferlach, T $u MLL Munich Leukemia Laboratory, Munich, Germany.
- 700 1_
- $a Haferlach, C $u MLL Munich Leukemia Laboratory, Munich, Germany.
- 773 0_
- $w MED00003138 $t Leukemia $x 1476-5551 $g Roč. 32, č. 2 (2018), s. 295-302
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/28751771 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20190405 $b ABA008
- 991 __
- $a 20190412121810 $b ABA008
- 999 __
- $a ok $b bmc $g 1392422 $s 1051417
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2018 $b 32 $c 2 $d 295-302 $e 20170728 $i 1476-5551 $m Leukemia $n Leukemia $x MED00003138
- LZP __
- $a Pubmed-20190405
